ERCC1基因多态性与大肠癌化疗疗效相关性的研究进展被引量：1

下载PDF

导出

摘要近年来，对大肠癌的研究和报道逐渐增多，对大肠癌的临床病理特征不断有新的认识。大肠癌是最常见的消化系统恶性肿瘤之一，其发病率和病死率都很高^[1]。在世界范围内，大肠癌的发病率在男性肿瘤中居第四位，在女性肿瘤中居第五位。在中国，根据国家卫生部在2006年所做的统计数据显示，我国大肠癌死亡率已上升至恶性肿瘤死亡率的第五位，发病率呈逐年上升的趋势，人群发病率高峰表现在60-75岁，已经严重危害到人们的健康。时至今日。

作者孔易白江涛郑纪宁

机构地区承德医学院

出处《承德医学院学报》 2013年第5期416-419,共4页 Journal of Chengde Medical University

关键词 ERCC1基因大肠癌化疗铂类药物

分类号 R735.3 [医药卫生—肿瘤]

引文网络
相关文献

参考文献23

1Parkin DM,Bmy F, Ferlay J, et al.Global cancer statislics.002[J]. CA Cancer J Clin,2005, 55(2):74-108. 被引量：1
2Park CH,Bessho T, Matsunaga T, et al.Purification and characterization of the XPF-ERCC1 complex of human DNA repair excision nuclease[J].J Biol Chem,1995,270(39):22657- 22660. 被引量：1
3Niedemhofer LJ,Odijk H,Budzowska M,et al.The structure- specific endonuclease Erccl-Xpf is required to resolve DNA inter strand cross-link-induced double-strand breaks[J].Mol Cell Bion,2004,24(13):5776-5787. 被引量：1
4Gazdar AF.DNA repair and stnafival in lung cancer-the two faces of Janus[J].N Engl J Med, 2007,356(8):771-773. 被引量：1
5Joshi MB,Shirota Y, Danenberg KD,et al.High gene expression of TSl,GSTPI,and ERCC1 are risk factors for survival in patients treated with trimodality hempy for 36 esophageal cancer[J]. Clin Cancer Rest2005,11 (6):2215-2221. 被引量：1
6温钦生,李邦华.结直肠癌组织中ERCC1表达与奥沙利铂耐药的研究进展[J].江西医药,2010,45(3):260-263. 被引量：6
7Wilson MD,Ruttan CC,Koop BF, et al.ERCC1 :a comparative genomic petspective[J].Environ Mol Mutagen,2001,38(2-3):209- 215. 被引量：1
8Sancar A, Reardon JT.Nucleotide excision repair in E. coil and rnan[J]Adv Protein Chem,2004, 69:43-71. 被引量：1
9Zhou W, Gurubhagavamla S, Liu G, et al.Excision repair cross- complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy[J].Clin Cancer Res,2004,10( 15):4939-4943. 被引量：1
10Stewart DJ. Mechanisms of resistance to cisplatin and caflxrplatin. [J]. Crit Rev Oncol Hematol, 2007,63( 1 ): 12- 31. 被引量：1

二级参考文献35

1Wilson MD,Ruttan CC,Koop BF,et al.ERCC1:a comparative genomic perspective.Environ Mol Mutagen,2001,38(2-3):209. 被引量：1
2Ali Z.Al Minawi,Yin Fai Lee,et al.The ERCC1/XPF endonuclease is required for completion of homologous recombination at DNA replication forks stalled by inter-strand cress-links.Nucleic Acids Res,2009,37(19):6400. 被引量：1
3Abbasi R,Ramroth H,Becher H,et al.Polymorphisms of DNA repair genes and risk of non-small cell lung cancer.Carcinogenesis,2006,27(3):560. 被引量：1
4Hector.S,Bolanowska-Higdon W,Zdanowicz J,et al.In vitro studies on the mechanisms of oxaliplatin resistance.Cancer Chemother Pharmacol,2001,48(5):398. 被引量：1
5Arnould S,Hennebelle I,Canal P,et al.Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.Eur J Cancer,2003,39(1):112. 被引量：1
6Balin Ganthier D,Delord JP,Pillaire MJ,et al.Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.Br J Cancer,2008,98(1):120. 被引量：1
7Paré L,Marcuello E,Altés A,et al.Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy.Br J Cancer,2008,99(7):1050. 被引量：1
8Kim SH,Kwou HE,Oh SY,et al.Prognostic value of ERCC1,thymidylate synthase,and glutathioue S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.Am J Clin Oncol,2009,32(1):38. 被引量：1
9Ruzzo A,Graziano F,Loupakis F,et al.Pharmacogenetic profiling in patients with advanced calorectal cancer treated with first-line FOLFOX-4 chemotherapy.Erratum in:J Clin Oncol,2009,27(19):3262. 被引量：1
10Park DJ,Zhang W,Stoehlmacher J,et al.ERCC1 gene polymorphism as a predictor for clinical outcome in advanced coloreetal cancer patients treated with platinum-based chemotherapy.Clin Adv Hematol Oncol,2003,1(3):162. 被引量：1